Lixte Biotechnology Holdings, Inc. Share Price
LIXTLixte Biotechnology Holdings, Inc. Stock Performance
Open $4.32 | Prev. Close $4.41 | Circuit Range N/A |
Day Range $4.32 - $4.51 | Year Range $0.64 - $6.14 | Volume 511 |
Average Traded $4.40 |
Lixte Biotechnology Holdings, Inc. Share Price Chart
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Lixte Biotechnology Holdings, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
12-Nov-25 | $4.32 | $4.41 | +0.00% |
12-Nov-25 | $4.32 | $4.41 | +2.56% |
11-Nov-25 | $4.27 | $4.30 | -0.46% |
10-Nov-25 | $4.25 | $4.32 | +1.89% |
07-Nov-25 | $4.30 | $4.24 | -1.17% |
06-Nov-25 | $3.92 | $4.29 | +6.98% |
05-Nov-25 | $4.12 | $4.01 | -2.43% |